EUVIMEDEUVIMED entdecken
Vergleichsstudie

A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer

Joo-Young Byun, Jinyong Kim, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Ju-Hwan Kim, Eui-Kyung Lee, Hyun Ae Jung

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115805 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Joo-Young Byun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Penn State College of Medicine, Hershey, PA, USA; School of Pharmacy, Sungkyunkwan University, Suwon, South Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Anaplastic Lymphoma Kinase, Carbazoles. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, South Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAnaplastic Lymphoma KinaseCarbazolesLactams, MacrocyclicAminopyridinesPiperidinesProtein Kinase InhibitorsHumansMaleFemaleMiddle AgedAgedAdultLactamsGene RearrangementTreatment OutcomePyrazoles

Stichwörter der Autor:innen

ALK rearranged non-small cell lung cancerAlectinibAsianLorlatinibMatching-adjusted indirect comparison

Substanzen

lorlatinibalectinibAnaplastic Lymphoma KinaseCarbazolesLactams, MacrocyclicAminopyridinesPiperidinesALK protein, humanLactamsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Surgery, Penn State College of Medicine, Hershey, PA, USA; School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: hyunae.jung@samsung.com.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT, South Korea

Zitieren

APA

Byun, J. Y., Kim, J., Park, S., Sun, J. M., Lee, S. H., Ahn, J. S., Ahn, M. J., Kim, J. H., Lee, E. K., & Jung, H. A. (2025). A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115805

Vancouver

Byun JY, Kim J, Park S, Sun JM, Lee SH, Ahn JS, et al. A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115805

BibTeX
@article{Byun2025,
  author = {Byun, Joo-Young and Kim, Jinyong and Park, Sehhoon and Sun, Jong-Mu and Lee, Se-Hoon and Ahn, Jin Seok and Ahn, Myung-Ju and Kim, Ju-Hwan and Lee, Eui-Kyung and Jung, Hyun Ae},
  title = {A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115805}
}
Kostenlos starten →